title: Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
authors: Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA. Michael.McFarland2@va.gov
authors: Michael Shawn
authors: MS
authors: McFarland
authors: Meghan
authors: M
authors: Brock
authors: Casey
authors: C
authors: Ryals
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; D052216:Glucagon-Like Peptide 1; D000218:Adamantane